The role of high-dose oral iron supplementation during erythropoietin therapy for anemia of prematurity

Journal of Perinatology

Volumn 21, Issue 4, 2001, Pages 215-220

  Bader, D ^a   Kugelman, A ^a   Maor Rogin, N ^a   Weinger Abend, M ^a   Hershkowitz, S ^a   Tamir, A ^a   Lanir, A ^a   Attias, D ^a   Barak, M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; STEROID;

AGE; ANEMIA; APNEA; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG MEGADOSE; DRUG POTENTIATION; ERYTHROCYTE TRANSFUSION; FEMALE; GESTATIONAL AGE; HEMATOCHEZIA; HEMATOCRIT; HEMOGLOBIN SYNTHESIS; HUMAN; INFANT; IRON THERAPY; LUNG DYSPLASIA; MALE; NECROTIZING ENTEROCOLITIS; PREMATURITY; RANDOMIZATION; RETICULOCYTE COUNT; SEPSIS;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANEMIA, NEONATAL; DRUG SYNERGISM; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRITINS; HEMATOCRIT; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; IRON; MALE;

EID: 0034870217     PISSN: 07438346     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jp.7200522     Document Type: Article

References (16)

1. Recombinant human erythropoietin in the treatment of anemia of prematurity: Results of a double-blind, placebo-controlled study
2. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants
3. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: A randomized, placebo-controlled trial
4. The effect of epoietin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants
5. Decreased ferritin level, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity
6. Postnatal changes in erythropoietin levels in untransfused premature infants
7. Potential for treatment of anemia of prematurity with recombinant human erythropoietin: Preliminary results
8. Anemia of prematurity: Progress and prospects
9. Erythropoietin, protein and iron supplementation and the prevention of anemia of prematurity
10. Erythropoietin (Epo), protein and iron supplementation and the prevention of anemia of prematurity: Effects on serum immunoreactive Epo, growth and protein and iron metabolism
11. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin
12. Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity: A randomized trial
13. Iron status of preterm low birth weight infants and their response to oral iron
14. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants
15. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: A randomized, placebo-controlled trial
16. Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: Results of a randomized, placebo-controlled, multicenter trial